CJC-1295 (with DAC)
Research Overview · Mechanism of Action · Reconstitution Guide
Overview
CJC-1295 with DAC incorporates a drug affinity complex — a maleimidoproprionic acid (MPA) moiety that forms a covalent bond with cysteine-34 on circulating albumin. This albumin conjugation dramatically extends the half-life to 6–8 days, enabling once-weekly or twice-weekly research dosing protocols. The trade-off is a blunted, non-pulsatile GH elevation rather than the sharp physiological pulses produced by the no-DAC variant.
Mechanism of Action
After subcutaneous injection, the reactive MPA group on CJC-1295 DAC covalently binds to albumin's free thiol group (Cys-34). The albumin-bound peptide circulates for days, continuously stimulating GHRH receptors and producing sustained GH elevation. This results in chronically elevated IGF-1 levels. The sustained (non-pulsatile) GH pattern differs fundamentally from physiological GH secretion and from the no-DAC variant, which has implications for receptor desensitization and downstream signaling in long-term research models.
Key Studies & References
Alba M et al. (2006). Once-monthly administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab 291:E1290–E1294.
Jetté L et al. (2005). hGRF1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats. Endocrinology 146:3052–3058.
Bacteriostatic Water Reconstitution Guide
Research Use Only — The following reconstitution information is provided for in vitro laboratory research purposes only. Not for human or veterinary use.
Recommended Solvent
Bacteriostatic water (0.9% benzyl alcohol)
Standard Volume
Add 2 mL bacteriostatic water to a 2 mg vial to yield a 1000 mcg/mL solution.
Working Concentration
1000 mcg/mL standard.
Storage (Reconstituted)
Reconstituted: 2–8°C, use within 28 days. Lyophilized: -20°C, desiccated.
Stability Window
28 days refrigerated. The DAC modification does not significantly affect solution stability.
Technique
Inject solvent slowly down the vial wall. Swirl gently until dissolved. Avoid vigorous agitation.
Notes
The DAC moiety is reactive — avoid contact with thiol-containing compounds or reducing agents in solution, as these may compete for the maleimide group prior to albumin binding.
Research Dosing Reference
The following dosing information is derived from published preclinical research literature and is provided for reference purposes only.
Clinical / Human Research Range
Human studies: 30–120 mcg/kg subcutaneous, single dose. Once-weekly protocols studied.
Preclinical Models
Rodent studies: 40–120 mcg/kg subcutaneous, weekly.
Calculation Example
For a 1000 mcg/mL solution: a 1 mg (1000 mcg) research dose = 1.0 mL.